Results 121 to 130 of about 11,416 (241)

Recent Advances in Ferrite‐Based Materials for Biomedical Applications: A Comprehensive Review

open access: yesAdvanced Materials, Volume 38, Issue 48, 26 August 2026.
Ferrite nanoplatforms are presented as tunable biomedical materials in which synthesis control, cation engineering, defect/morphology regulation, and surface functionalization govern structure–property–bioactivity relationships. These design strategies enable multifunctional applications including MRI contrast, magnetic hyperthermia, targeted drug ...
Pramod D. Mhase   +6 more
wiley   +1 more source

Negotiating in a Foreign Land: Understanding the Curious Interactions Between Intracellular Mitochondria and Internalized Nanoparticles

open access: yesAdvanced Materials Interfaces, Volume 13, Issue 16, 18 August 2026.
Therapeutic nano‐drug delivery systems interact with cellular mitochondria in a multitude of ways. While the complexity of such interactions disrupts the mitochondrial electron transport chain and increases reactive oxygen species production, thereby contributing to nanoparticle toxicity, they also present unique theranostic opportunities in diseases ...
Sourav Bhattacharjee
wiley   +1 more source

β‐Elemene Rescues Radiation‐Induced Enteritis by Orchestrating a Host‐Microbiome Circuit That Fuels Epigenetic DNA Repair

open access: yesAdvanced Science, Volume 13, Issue 47, 24 August 2026.
This study elucidates that β‐elemene promotes cellular uptake of L. gasseri‐derived lactate by enhancing the membrane translocation of MCT1 in a CD147‐dependent manner. Intracellular lactate, through the lactylation of RBBP4 at the K26 site, recruits EP300 to the promoter regions of downstream genes (POLD1/POLD3), catalyzing H3K27ac modification.
Jiancheng He   +10 more
wiley   +1 more source

Epigenetic Silencing of RFX7 Defines a Transcriptional Axis Linking Lactate Metabolism to Immune Checkpoint Therapy in Glioblastoma

open access: yesAdvanced Science, Volume 13, Issue 45, 13 August 2026.
Glioblastoma (GBM) exhibits RFX7 silencing via promoter hypermethylation, which downregulates PIK3IP1 to activate PI3K/AKT signaling, increase lactate accumulation, and enhance histone H4K12 lactylation. This lactylation upregulates PD‐L1/CSF1 expression and drives the immunosuppressive microenvironment formation.
Liying Han   +20 more
wiley   +1 more source

All‐Flex Plasma Patch for In Vivo Delivery of Reactive Species

open access: yesAdvanced Science, Volume 13, Issue 45, 13 August 2026.
A fully flexible plasma patch enables stable, conformal treatment on complex biological surfaces and enhances transdermal delivery of reactive species. This platform achieves significant tumor suppression in vivo and reveals coordinated regulation of calcium signaling, metabolism, and programmed cell death, providing a promising strategy for safe and ...
Luxiang Zhao   +8 more
wiley   +1 more source

Metabolic and morphological assessment of carbon ion radiotherapy response in sacral chordoma. [PDF]

open access: yesPhys Imaging Radiat Oncol
Gantumur B   +8 more
europepmc   +1 more source

Therapeutic Applications of Stimuli‐Based Release and Engineering of Extracellular Vesicles

open access: yesAdvanced NanoBiomed Research, Volume 6, Issue 8, August 2026.
This review summarizes the effects of endogenous and exogenous stimuli, their effects on the natural release of extracellular vesicles, as well as their uptake and release. It also gives an overview of stimuli‐responsive EVs and their therapeutic applications. Extracellular vesicles (EVs), nano‐ to microsized lipid bilayer membrane‐bound particles, are
Gloria Kemunto, Kristen Dellinger
wiley   +1 more source

Carbon ion radiotherapy at NIRS

open access: yesCarbon ion radiotherapy at NIRS
In 1994, carbon ion radiotherapy was begun at the National Institute of Radiological Sciences using the Heavy Ion Medical Accelerator in Chiba, which was the worlds 􀂿rst heavy ion accelerator complex dedicated to medical use in a hospital environment. Among several types of ion species, carbon ions were selected for cancer therapy because they
openaire  

Predicting Poor Efficacy of Cabozantinib in Advanced Renal Cell Carcinoma by Exploratory Metabolic Pathway Analysis and In Vitro Verification

open access: yesCancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Background Cabozantinib (CABO) is currently an essential drug for first‐line and sequential therapy in the treatment of advanced renal cell carcinoma (RCC). Predicting its therapeutic efficacy will enable efficient drug selection and improve the prognosis of patients.
Takanari Sakai   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy